Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

This article discusses several significant developments in the biotech and pharmaceutical sectors. The FDA rejected Moderna’s mRNA-based flu vaccine, citing an inadequate comparator group, and also rejected Disc Medicine’s rare disease drug bitopertin due to regulatory uncertainty. Meanwhile, Compass Pathways reported strong Phase 3 data for its psilocybin-based depression drug, and the CDC is once again leaderless following the departure of Jim O’Neill.